Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
•
Prostate Cancer
Would you offer modest hypofractionation (e.g. 70 Gy/28 fractions) to a patient with intermediate risk prostate cancer and celiac disease?
Answer from: Radiation Oncologist at Community Practice
Celiac disease is primary small bowel disease. RT effect on rectum would not be exaggerated from the disease.
Sign In
or
Register
to read more
5901
Related Questions
How does the presence of indeterminate lymphadenopathy on PSMA PET scan alter your management of unfavorable intermediate-risk prostate cancer?
Which patients, if any, do you offer transdermal estradiol as a method of ADT instead of LHRH agonists?
Do you recommend neoadjuvant 177Lu-PNT2002 followed by MDT per the LUNAR trial as your preferred treatment approach for oligorecurrent prostate cancer, as opposed to MDT and PSMA-radioligand therapy used as temporally separate treatments?
How do you approach ADT in patients with high-risk prostate cancer who have risk factors for VTE, such as Factor V Leiden?
Is there any evidence that ivermectin suppresses the PSA level in prostate cancer?
How do you interpret recent large retrospective analyses comparing radical prostatectomy vs. radiation for prostate cancer?
Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?
Does long term use of 5 alpha reductase inhibitors change the way you evaluate a PSMA PET?
How do you interpret isolated PSMA-avid sites in a patient with prostate cancer with no pelvic or RP LN uptake?
Would you add whole-pelvis radiation as MDT (metastasis-directed therapy) in a patient with 1 pelvic node and 2 osseous metastatic sites for castrate-resistant prostate cancer?